The online version of this article (doi:10.1186/s12974-017-0848-z) contains supplementary material, which is available to authorized users.
Mitochondria are abundant organelles critical for energy metabolism and brain function. Mitochondrial DNA (mtDNA), released during cellular injury and as part of the innate immune response to viral pathogens, contains CpG motifs that act as TLR-9 ligands. We investigated relationships between cerebrospinal fluid (CSF) cell-free mtDNA levels and HIV viral load (VL), biomarkers of inflammation and iron transport, and neurocognitive (NC) function in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort.
We quantified cell-free mtDNA in CSF by droplet digital PCR in 332 CHARTER participants who underwent comprehensive neuropsychiatric evaluation. NC performance was assessed using the global deficit score (GDS) as either a continuous or a binary measure (GDS ≥ 0.5, impaired vs. GDS < 0.5, unimpaired). CSF, clinical, and biomarker data from the earliest available time point were analyzed. Cell-free mtDNA associations with CSF inflammation and iron-related biomarkers [CXCL10, IL-6, IL-8, TNF-a, transferrin (TF), ceruloplasmin (CP), and vascular endothelial growth factor (VEGF)], VL, and GDS were evaluated by multivariable regression.
CSF cell-free mtDNA levels were significantly lower in participants with undetectable (vs. detectable) VL in either plasma (p < 0.001) or CSF (p < 0.001) and in those on antiretroviral therapy (ART; p < 0.001). Participants on ART with undetectable VL in both CSF and plasma had lower mtDNA levels than those with detectable VL in both compartments (p = 0.001). Higher mtDNA levels were observed in participants in the highest vs. lowest tertile (T3 vs. T1) of CSF CXCL10 (T3 vs. T1, p < 0.001) and TNF-a (T3 vs. T1, p < 0.05) in unadjusted analyses. MtDNA levels also correlated with CSF leukocyte count. After adjusting for CSF leukocyte count and VL, mtDNA levels were also associated with other inflammation- and iron-related biomarkers in CSF, including TF (T3 vs. T1, p < 0.05) and CP (T3 vs. T1, p < 0.05). With additional correction for ART use, mtDNA was also negatively associated with CSF VEGF (p < 0.05) and IL-6 (p = 0.05). We observed no associations of CSF mtDNA levels with age or GDS-defined NC impairment.
CSF cell-free mtDNA levels were associated with HIV RNA and ART status, as well as with biomarkers of iron transport and VEGF, a growth factor with known effects on mitochondrial integrity and autophagy. CSF mtDNA may be a biomarker of iron dysregulation and/or neuroinflammation during HIV infection.
Additional file 1: Table S1. Categorization of the 216 individuals with follow-up neurocognitive assessments. Baseline assessments were compared to the assessment at the last follow-up visit, and individuals were categorized as improved, stable, or declined. Table S2. Univariate analyses of log CSF-free mtDNA and CSF biomarkers of inflammation and iron transport. (DOCX 12 kb)
Lane RK, Hilsabeck T, Rea SL. The role of mitochondrial dysfunction in age-related diseases. Biochim Biophys Acta. 1847;2015:1387–400.
Pinto M, Moraes CT. Mitochondrial genome changes and neurodegenerative diseases. Biochim Biophys Acta. 1842;2014:1198–207.
Var SR, Day TRC, Vitomirov A, Smith DM, Soontornniyomkij V, Moore DJ, et al. Mitochondrial injury and cognitive function in HIV infection and methamphetamine use. AIDS Lond Engl. 2016;30:839–48. CrossRef
Coskun P, Wyrembak J, Schriner SE, Chen H-W, Marciniack C, LaFerla F, et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta BBA - Gen Subj. 1820;2012:553–64.
Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60:473–80. CrossRef
Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42:679–88. CrossRefPubMed
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS Lond Engl. 2011;25:1747–51. CrossRef
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. Available from: URL http://www.R-project.org/.
Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, et al. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clin Chim Acta Int J Clin Chem. 2016;452:109–19. CrossRef
Liu J, Cai X, Xie L, Tang Y, Cheng J, Wang J, et al. Circulating cell free mitochondrial DNA is a biomarker in the development of coronary heart disease in the patients with type 2 diabetes. Clin Lab. 2015;61:661–7. PubMed
Sudakov NP, Popkova TP, Katyshev AI, Goldberg OA, Nikiforov SB, Pushkarev BG, et al. Level of Blood Cell-Free Circulating Mitochondrial DNA as a Novel Biomarker of Acute Myocardial Ischemia. Biochem. 2015;80:1387–92.
Pérez-Santiago J, Schrier RD, de Oliveira MF, Gianella S, Var SR, Day TRC, et al. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. J Neurovirol. 2015;22(2):191-200.
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet Lond Engl. 2016;388(10043):518-29.
Lowndes SA, Harris AL. Copper chelation as an antiangiogenic therapy. Oncol Res. 2004;14:529–39. PubMed
Burkhart A, Skjørringe T, Johnsen KB, Siupka P, Thomsen LB, Nielsen MS, et al. Expression of iron-related proteins at the neurovascular unit supports reduction and reoxidation of iron for transport through the blood-brain barrier. Mol Neurobiol. 2016;53(10):7237-53.
Arber CE, Li A, Houlden H, Wray S. Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathol Appl Neurobiol. 2015;42(3):220-41.
Simpson IA, Ponnuru P, Klinger ME, Myers RL, Devraj K, Coe CL, et al. A novel model for brain iron uptake: introducing the concept of regulation. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2015;35:48–57. CrossRef
McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, et al. Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery. J Crit Care. 2014;29:1133.e1–5. CrossRef
Borgmann K, Ghorpade A. HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Front Microbiol. 2015;6:1143.
Dickens AM, Anthony DC, Deutsch R, Mielke MM, Claridge TDW, Grant I, et al. Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS Lond Engl. 2015;29:559–69.
- Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment
Sanjay R. Mehta
Tyler R. C. Day
Jesse D. Suben
David B. Clifford
Ann C. Collier
Christina M. Marra
Benjamin B. Gelman
- BioMed Central